Eagle Pharmaceuticals Reports First Quarter 2023 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 33c; Offers FY23 EPS Guidance
May 9, 2023 6:52 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.26, $0.33 better than the analyst estimate of $0.93. Revenue for the quarter came in at $66.3 million versus the consensus estimate of $63.29 million.
GUIDANCE:
Eagle Pharmaceuticals sees FY2023 EPS of $4.20-$4.53, versus the consensus of... More
